DNAs from human pancreatic adenocardnomas were analyzed for the presence of mutations in codons 12, 13 and 61 of the NRAS,
INTRODUCTION
Mutated RAS genes have been detected in a broad range of human cancers [1] . For instance, half of the colon tumors [2] [3] [4] and a third of the lung adenocarcinomas [5] and the acute myeloid leukemias [6, 7] harbor a mutated RAS gene. In all cases the mutation was found in codon 12, 13 or 61 of one of the three genes, NRAS, KRAS and HRAS, although there is some specificity in that NRAS mutations predominate in heraatopoietic malignancies and KRAS mutations in colon tumors and lung adenocarcinomas.
Tumors of the acinar cells of the exocrine pancreas are the fourth common tumor in the western world and invariably result in the patients death.
Recently, Alraoguera and coworkers [8] reported that mutations in or around codon 12 of the KRAS gene occur in 21 of the 22 pancreas adenocarcinomas analyzed. The RNAse A mismatch cleavage procedure used, however, does not allow the exact determination of the mutations. The knowledge of the mutation is important to evaluate whether specific chemical mutagens are involved in the mutational event. Furthermore, we would like to know whether tumors which do not contain a mutation in or around codon 12 of the KRAS gene may have a mutation in codon 61 of the KRAS gene or in one of the other RAS genes. We therefore analyzed a series of 30 pancreatic adenocarcinomas using our procedure of selective hybridization with synthetic oligonucleotides [9, 10] . In this procedure we hybridize tumor DNA with oligonucleotides specific for mutations that can activate a normal RAS gene into an oncogene.
In this paper we confirm the high incidence of RAS mutations in pancreatic adenocarcinomas. The mutations were exclusively in codon 12 of the KRAS gene. The spectrum of mutations found is similar to the KRAS 12 mutations in lung adenocarcinomas but differs from the KRAS mutations in colon tumors. The results will be discussed in terms of possible chemical mutagens involved in the mutation of the KRAS gene.
MATERIAL AND METHODS

Tumor material
Formalin-fixed, paraffin-embedded pancreatic carcinoma tissues were obtained from the University Hospital and the Diaconnessen Hospital, Leiden. The oldest samples were from 1973, the most recent from 1988. A section of paraffin blocks was stained with hematoxylin and eosin and examined for the presence of tumor cells. Three adjacent lOpM sections were taken and used in the analysis of mutated RAS gene.
In vitro amplification
One lOuM section was used for each amplification. The amplification was essentially as described by Shibata et al. [11] with minor modifications. After deparaffination the tissue was suspended in lOOpl H2O and incubated for 10 min at 100" C. Subsequently, 20pl of a mixture was added containing buffer, dNTPs, primer and DNA polymerase. The final concentrations were: 50mM KCl, lOmM Tris.Cl pH8.3, 3mM MgCl2, 0.01% bovine serum albumine, 200pM each dNTP, luM each primer and 2 units Taq-DNA polymerase (BIORES, Woerden, The Netherlands). The samples were cycled 40 times at 72*C, 94*C and 56*C, each for 1.5 min, using a robot-arm and three separate waterbaths.
Subsequently, the specificity of the amplification was renewed by the addition of (2 units) , and another 40 cycles were performed. The primers used are shown in Table I . Normally, we amplify the regions around codon 12 of the three RAS genes simultaneously and, subseguently, the regions around codon 61. For the pancreatic tumors we have first amplified the region around codon 12 of the KRAS gene and only the samples negative for mutations in codon 12 or 13 of the KRAS gene were amplified for the other regions. Selective hybridization
Selective hybridizations using oligonucleotide probes of 20 nucleotides length were performed as described by Verlaan-de Vries et al. [10] .
RESULTS
Thirty seven samples of formalin-fixed and paraffin-embedded tissue, most of which contained adenocarcinomas of the exocrine pancreas, were histologically characterized and the percentage of tumor cells in the sample was estimated. The samples were deparaffinized and relevant sequences of the three RAS genes were in vitro amplified by a procedure essentially as described by Shibata and coworkers [11] .
We first amplified sequences comprising codons 12 and 13 of the KRAS gene. This in vitro amplified material was spotted onto 13 nylon membranes and hybridized to an oligomer complementary to the normal KRAS sequence in and around codon 12 and to 12 other oligomers complementary to all possible single point mutations that lead to an amino acid change in codon 12 or 13. Hybridization conditions were chosen so that only a fully matched hybrid remains. Only the autoradiograms that show positive hybridizations are shown in Figure 1 . In examining these autoradiograms one should keep in mind that each tumor sample is independently amplified. Since the efficiency of amplification will vary, the amount of DNA spotted onto the membrane will also be variable. Therefore, one should not compare the intensity of the hybridization signal of the different tumor samples. Since the specific radioactivity of each of the oligomers is similar the different hybridization signals of an individual sample can be compared. In principle, the mutation-specific and the normal (gly) hybridization signal should be of equal intensity assuming that only one allele is mutated and that the sample does not contain normal tissue. Most of the samples, however, contain considerable amounts of normal tissue (see Table II ) which should reduce the mutation-specific signal. In some cases a stronger mutation-specific signal is found (see for instance sample 22) indicating that the tumor cells have lost the normal KRAS allele. Finally, with some samples, a weak mutation-specific signal is observed in addition to a strong mutation-specific signal with another oligomer probe (e.g. samples 10, 16, 34, 36) . This might suggest tumor heterogeneity, but the signals are too weak compared to the normal signal to draw firm conclusions. Our interpretation of the results is summarized in Table II mutation is present in the tumor tissue. One of these positive samples was a repeat sample from the same patient. All the positive samples were pancreatic adenocarcinoraas. Four samples did not contain sufficient tumor cells to allow detection by our procedure. In routine analyses we are able to detect a point mutation when it is present in 10-20% of the cells in the sample. Finally, four samples with sufficient tumor cells did not harbor a mutation in codon 12 or 13 of the KRAS gene. Only two of these . no mutation detectable. *. Only for clear cases the loss of the normal allele is indicated.
samples were pancreatic adenocarcinomas. The other two samples were a carcinoma of the papil of Vater and a stomach carcinoma, which were added as control samples. Thus, 28 of the 30 patients with an adenocarcinoma of the exocrine pancreas and with sufficient tumor cells in the sample to allow detection of RAS mutations by our procedure contain a mutation in codon 12 of the KRAS gene. Three mutations, G to T at the first base of the codon To evaluate whether the type of mutations found in codon 12 of the KRAS gene in pancreatic adenocarcinomas exhibit a certain specificity we have compared these mutations with KRAS mutations occurring in colon tumors [4] and in lung adenocarcinomas [6] . As shown in table III the predominant mutation in the pancreas are G-T tranversions. The spectrum of mutations in the pancreas is similar to the spectrum in lung, but differs from that in colon tumors. In the latter tumors G-A transitions are more frequently present.
DISCUSSION
Twenty-eight of the 30 patients with a tumor of the exocrine pancreas harbor a mutated RAS gene in the tumor DNA and in all cases the mutation is in codon 12 of the KRAS gene. These results indicate that mutational activation of the KRAS gene might be a critical event in the development of pancreatic adenocarcinoraas. In two cases RAS gene mutations could not be detected in the tumor DNA, although histologically these tumors do not differ from the tumors with a mutated RAS gene. It might be that in these cases the RAS genes incurred a mutation at a position which we did not screen. Alternatively, other defects with a similar effect as the mutational activation of the KRAS gene may have taken place. The relevance of activated RAS genes in the development of pancreatic tumors is further illustrated by experiments with transgenic mice which harbored a mutated HRAS gene under control of the elastase I promoter [12] . These mice developed carcinomas of all the fetal pancreas cells directly after the onset of elastase gene expression. indicating that the expression of a mutant HRAS gene is sufficient for the development of the tumor. This result, however, does not imply that for the development of spontaneous pancreatic tumors a single activated RAS gene is sufficient. In the latter case the RAS gene mutation arises in a single cell which, subsequently, has to grow out in the presence of the surrounding normal cells, whereas in the transgenic mice model all fetal pancreatic cells had the mutant RAS protein. A secondary event might be necessary to overcome possible inhibitory effects of normal cells. One of the events that may play an additional role in the development of human pancreatic tumors is the loss of the normal KRAS allele. This loss might reflect the loss of a putative tumor suppressor gene which is located in the vicinity of the KRAS gene. Alternatively, the normal KRAS allele may be lost by gene conversion resulting in two mutant alleles. Such a duplication can be important as has been shown for the HT1080 fibrosarcoma cell line. In this cell a single mutated NRAS allele, is not sufficient for the tumorigenicity of the cells [13] . Finally, the loss of the normal KRAS allele might prevent competition between the normal and the mutant KRAS protein. Evidence for such a competition is lacking, however.
The most striking observation is that all mutations occur in codon 12 of the KRAS gene. On the contrary, activated RAS proteins are considered to act autonomously in the activation of an effector molecule (protein). Recently, a putative effector protein, GAP, has been identified which binds to a domain identical in all three RAS proteins [14, 15] . This indicates that all three RAS proteins might have the same effector molecule.
A final explanation for the occurrence of unique mutations in the KRAS gene might be a different susceptibility to specific carcinogens.
The KRAS mutations found in pancreatic carcinomas are mainly G-T transversions at the first or second base and a G-A transition at the second base of codon 12. This mutation spectrum is similar to the spectrum found in lung carcinomas, but differs from that in colon tumors [ Table III ]. These differences might be due to tissue-specific factors, such as susceptibility to specific carcinogens or activity of certain DNA repair mechanisms, but could also reflect different chemical mutagens involved in the induction of these tumors.
Indeed, from experiments with animal model systems it has been shown that different chemical mutagens can cause different mutations in the RAS genes [16] . With respect to pancreatic cancer, several chemical agents are used for the induction of tumors in a variety of animal models [17] [18] [19] . It is unknown, however, whether in these chemically induced pancreatic tumors mutated RAS genes are present. In humans, no direct causal relationship between any chemical agent and pancreatic carcinogenesis is found. From several epidemiological studies it appears that cigaret smoking is the only well established risk factor [20] [21] [22] . In this connection it is striking that the mutation spectrum found in pancreatic tumors is similar to that in lung tumors where smoking is an important factor in the induction of the KRAS mutation. The mutation spectra presented in this paper might help to identify chemical mutagens that specifically can induce mutations in the KRAS gene and, thus, represent risk factors for the induction of the major human cancers.
